about
Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patientsGut microbiota: a key player in health and disease. A review focused on obesity.Effects of lipoic acid on lipolysis in 3T3-L1 adipocytes.Role of mitochondria in HIV infection and associated metabolic disorders: focus on nonalcoholic fatty liver disease and lipodystrophy syndrome.Multiple frequency bioimpedance is an adequate tool to assess total and regional fat mass in HIV-positive patients but not to diagnose HIV-associated lipoatrophy: a pilot studyLack of Adrenomedullin Results in Microbiota Changes and Aggravates Azoxymethane and Dextran Sulfate Sodium-Induced Colitis in Mice.Deciphering the molecular mechanisms involved in HIV-associated lipoatrophy by transcriptomics: a pilot study.Thawing as a critical pre-analytical step in the lipidomic profiling of plasma samples: New standardized protocol.Effects of alpha-lipoic acid on chemerin secretion in 3T3-L1 and human adipocytes.High prevalence of asymptomatic carriers of Tropheryma whipplei in different populations from the North of Spain.Maraviroc ameliorates the increased adipose tissue macrophage recruitment induced by a high-fat diet in a mouse model of obesity.Limited beneficial effects of piceatannol supplementation on obesity complications in the obese Zucker rat: gut microbiota, metabolic, endocrine, and cardiac aspects.Potential renoprotective effects of piceatannol in ameliorating the early-stage nephropathy associated with obesity in obese Zucker rats.α-Lipoic acid treatment increases mitochondrial biogenesis and promotes beige adipose features in subcutaneous adipocytes from overweight/obese subjects.Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD).Lipoic acid administration prevents nonalcoholic steatosis linked to long-term high-fat feeding by modulating mitochondrial function.Lipoic acid inhibits adiponectin production in 3T3-L1 adipocytes.Erythrocyte antioxidant defenses as a potential biomarker of liver mitochondrial status in different oxidative conditions.α-lipoic acid reduces fatty acid esterification and lipogenesis in adipocytes from overweight/obese subjects.Agaricus bisporus supplementation reduces high-fat diet-induced body weight gain and fatty liver developmentEffects of the amino acid derivatives, β-hydroxy-β-methylbutyrate, taurine, and N-methyltyramine, on triacylglycerol breakdown in fat cellsPlasma lipidomic profiling method based on ultrasound extraction and liquid chromatography mass spectrometryThe influence of interferon β-1b on gut microbiota composition in patients with multiple sclerosisImpact of dietary lipoic acid supplementation on liver mitochondrial bioenergetics and oxidative status on normally fed Wistar ratsCharacterization of gut microbiota composition in HIV-infected patients with metabolic syndromeShort-term effects of direct-acting antiviral agents on inflammation and gut microbiota in hepatitis C-infected patients
P50
Q33787675-74C7CA35-EDEC-4D6C-AC20-D6D55D7BCE9FQ35573445-073B993F-FCB5-4CC9-A71C-B44FD61009EDQ36302718-7F7C17D7-DEB2-4C1C-A8E8-6BAE3DC14F28Q37077573-D7AEA3A9-01F8-470C-8E43-32B6E2B5A6FAQ37419698-BEE5F102-8715-41EC-943C-73C536613222Q37452479-711665A1-12A1-4352-A394-7CCA0F5EA8F0Q38438251-F81F7B96-4CB5-482F-8DF4-2BED996A5618Q39964695-554BBCD6-1193-4766-9125-4CADC4755D0CQ40154228-340A1EC6-1F2F-4D85-8265-18F4DB68CEB6Q40300450-C0E014F8-4609-4B9A-A937-9C54DED40071Q40511313-7A68D24F-DF38-43C6-AED8-38FCA54D70CEQ40824062-6481C0FF-97B0-48F5-9D9E-83A9CDEA8466Q40873779-17959244-505C-46C5-A00B-051EE036E723Q41580218-5CD8CEA7-5DF1-49AA-BDAF-11FACC5F3CCCQ42222958-9291C355-FB54-4BFE-A9B3-183A10DAB2FDQ42719534-F0AC49AA-1DD3-495E-A404-611B4FE6C9C1Q42826875-22797FE0-5B3A-4E68-ACA0-93D613797A65Q51173989-8EB2EA46-996D-43C6-AAE9-0749ECCE5511Q54336302-2D03D700-50AB-4FF0-91C1-34AF31ECC397Q57028919-F6B3ADFB-ECAA-428B-87A8-4211C137094BQ64039666-6D9A034E-A746-48A9-8D2A-F6304537B0CCQ86830173-F22361C9-9C8A-416E-8AE1-903A1A749161Q89080464-474F448B-8235-49A0-BE04-052EC495464DQ91588375-0698B41E-DFCE-4BEE-80B4-932BE7D3F90CQ92691982-C3BD2288-354D-4D85-B717-84A4C9D22A0EQ92914957-C2E8E48C-5F37-4B52-B38D-BEF5AACC2B6D
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Patricia Pérez-Matute
@en
Patricia Pérez-Matute
@nl
type
label
Patricia Pérez-Matute
@en
Patricia Pérez-Matute
@nl
prefLabel
Patricia Pérez-Matute
@en
Patricia Pérez-Matute
@nl
P31
P496
0000-0003-2232-7971